Skip to main content
Premium Trial:

Request an Annual Quote

Epistem Aims to Raise £2.8M

NEW YORK (GenomeWeb News) – Epistem Holdings said that it plans to raise £2.8 million ($4.4 million) through the placement of 793,398 new ordinary shares at 350 pence each.

The offering price is a slight discount to the trading price of around 362.5 pence before the placement was announced Friday. The Manchester, UK-based firm said that it has conditionally placed the shares with unnamed existing and new institutional investors.

Epistem plans to use the proceeds from the placement to accelerate development of its Genedrive point-of-care device for molecular diagnostics, pharmacogenomics, biodefense, and forensic applications. The firm said the system, which it is developing for bacterial, viral, fungal, and gene mutations, is in clinical trials across a number of diagnostic areas.

Epistem also has biomarker deals with several pharmaceutical firms including Sanofi-Aventis, Novartis, AstraZeneca, and Johnson & Johnson.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.